2017 White Paper: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies' inputs).
暂无分享,去创建一个
Hao Jiang | Amanda Wilson | Eric Woolf | Jian Wang | Sam H Haidar | An Song | Akiko Ishii-Watabe | Makoto Niwa | Keyang Xu | Fabio Garofolo | Sam Haidar | Natasha Savoie | Nilufer Tampal | Jan Welink | Hendrik Neubert | Yoshiro Saito | Olivier Le Blaye | Emma Whale | Shashi Amur | Lorella Di Donato | João Pedras-Vasconcelos | Anita Lee | Joe Palandra | Laurent Cocea | John Kadavil | Gustavo Mendes Lima Santos | Stephen Vinter | Seongeun Julia Cho | Omar Laterza | Matthew Szapacs | Sam H. Haidar | Eugene Ciccimaro | Hao Jiang | S. Amur | Kai Liu | Yoshiro Saito | Eugene Ciccimaro | Shang-Chiung Chen | O. Laterza | L. Donato | Amanda Wilson | M. Bustard | I. Cludts | H. Neubert | S. Cho | Stephen Vinter | P. Kurki | E. Woolf | J. Welink | M. Qian | F. Garofolo | J. Palandra | M. Cancilla | Ola Saad | M. Szapacs | Sean Kassim | Natasha Savoie | Emma Whale | C. D’arienzo | Dian Su | Keyang Xu | Cong Wei | Jeff Duggan | Chris Evans | Isabella Berger | Mark Bustard | Mark Cancilla | Shang-Chiung Chen | Isabelle Cludts | Celia D'Arienzo | Lieza Danan-Leon | Sean Kassim | Pekka Kurki | Kai Liu | Rod Mathews | Mark Qian | Brian Rago | Dian Su | Y-J Xue | Anita Y H Lee | C. Evans | A. Song | Matthew E. Szapacs | Anita Y. H. Lee | Ola M. Saad | Jeffrey X. Duggan | Jeffrey X Duggan | Jian Wang | Isabella Berger | L. Cocea | John Kadavil | J. Pedras-Vasconcelos | N. Tampal | Cong Wei | Brian Rago | M. Niwa | Y-J Xue | Lieza M. Danan-Leon | A. Ishii-Watabe | Roderick B. Mathews | Shashi Amur | L. D. Donato
[1] Sam H Haidar,et al. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays). , 2017, Bioanalysis.
[2] Sam H Haidar,et al. 2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines 'Scientific'? (Part 1 - LCMS: small molecules, peptides and small molecule biomarkers). , 2017, Bioanalysis.
[3] Eugene Ciccimaro,et al. Antibody Drug-Target Engagement Measurement in Tissue Using Quantitative Affinity Extraction Liquid Chromatography-Mass Spectrometry: Method Development and Qualification. , 2017, Analytical Chemistry.
[4] Stefani N. Thomas,et al. Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain. , 2017, Methods in molecular biology.
[5] Sam H Haidar,et al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity). , 2016, Bioanalysis.
[6] Barry Jones,et al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies). , 2016, Bioanalysis.
[7] J. Bauman,et al. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. , 2016, ACS chemical biology.
[8] Stephanie Cape,et al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 - small molecules, peptides and small molecule biomarkers by LCMS). , 2016, Bioanalysis.
[9] Jeffrey X. Duggan,et al. LC-MS quantification of protein drugs: validating protein LC-MS methods with predigestion immunocapture. , 2016, Bioanalysis.
[10] Michael E. Lassman,et al. An evaluation of an aptamer for use as an affinity reagent with MS: PCSK9 as an example protein. , 2016, Bioanalysis.
[11] Eugene Ciccimaro,et al. Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC-MS. , 2016, Bioanalysis.
[12] L. Fitz,et al. Quantitative measurements of GDF‐8 using immunoaffinity LC‐MS/MS , 2016, Proteomics. Clinical applications.
[13] Sheldon S Leung,et al. Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice , 2016, mAbs.
[14] Lin-Zhi Chen,et al. Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation , 2016, Journal of immunology research.
[15] Renuka Pillutla,et al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity). , 2015, Bioanalysis.
[16] Surinder Kaur,et al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 - hybrid LBA/LCMS and input from regulatory agencies). , 2015, Bioanalysis.
[17] Roger Hayes,et al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 - small molecules by LCMS). , 2015, Bioanalysis.
[18] Jeffrey R. Whiteaker,et al. Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Enables Multiplex, Quantitative Pharmacodynamic Studies of Phospho-Signaling* , 2015, Molecular & Cellular Proteomics.
[19] Hao Jiang,et al. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays. , 2015, Journal of immunological methods.
[20] Lindsay King,et al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity). , 2014, Bioanalysis.
[21] Lindsay King,et al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input). , 2014, Bioanalysis.
[22] Li Xue,et al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1--small molecules by LCMS). , 2014, Bioanalysis.
[23] R. Dodge,et al. Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development. , 2014, Analytical Chemistry.
[24] Stacy Ho,et al. 2013 White Paper on recent issues in bioanalysis: 'hybrid'--the best of LBA and LCMS. , 2013, Bioanalysis.
[25] Roger Hayes,et al. Recommendations on biomarker bioanalytical method validation by GCC. , 2012, Bioanalysis.
[26] Sam H Haidar,et al. 2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines. , 2012, Bioanalysis.
[27] Stacy Ho,et al. 2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections. , 2011, Bioanalysis.
[28] Eric Woolf,et al. 2010 white paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance. , 2010, Bioanalysis.
[29] Hendrik Neubert,et al. Online high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS: assay development for total salivary pepsin/pepsinogen. , 2010, Clinical chemistry.
[30] Xia Yin,et al. 2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group Workshop. , 2010, Bioanalysis.
[31] Fabio Garofolo,et al. The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis. , 2009, Bioanalysis.
[32] David M Holtzman,et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.